Document:

Exhibit 10.1

 

Board
of DIRECTORs AGREEMENT

 

This Board of Directors Agreement (“Agreement”) made
effective as December 6, 2021, by and between BIMI International Medical Inc., with its principal place of business at 9th Floor,
Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P.R.China (the “Company”) and _____, with an
address at _______________________________________ (“Director”), provides for director services, according to the
following terms and conditions:

 

I. Services Provided

 

The Director agrees, subject to the Director’s continued status as
a director, to serve on the Company’s Board of Directors (the “Board”) and to provide those services required of a director
under the Company’s Certificate of Incorporation and Bylaws, as both may be amended from time to time (“Articles and Bylaws”)
and under the Delaware General Corporation Law, the federal securities laws and other state and federal laws and regulations, as applicable,
and the rules and regulations of the Securities and Exchange Commission (the “SEC”) and any stock exchange or quotation system
on which the Company’s securities may be traded from time to time.  Director will also serve on such one or more committees
of the Board as he or she and the Board shall mutually agree.  

 

It is acknowledged that the Director has been serving on the Board
prior to the date of this Agreement upon the election by the stockholders of the Company (the “Existing Board Services”),
and the signing of this Agreement shall not alter the terms or conditions of the Existing Board Services in any aspect unless otherwise
specified in this Agreement.

 

II. Nature of Relationship

 

The Director is an independent contractor and will not be deemed as
an employee of the Company for any purposes by virtue of this Agreement.  The Director shall be solely responsible for the payment
or withholding of all federal, state, or local income taxes, social security taxes, unemployment taxes, and any and all other taxes relating
to the compensation he or she earns under this Agreement.  The Director shall not, in his or her capacity as a director of the Company,
enter into any agreement or incur any obligations on the Company’s behalf, without appropriate Board action.

 

The Company will supply, at no cost to the Director:  periodic
briefings on the business, director packages for each board and committee meeting, copies of minutes of meetings and any other materials
that are required under the Company’s Articles and Bylaws or the charter of any committee of the Board on which the Director serves
and any other materials which may, by mutual agreement, be necessary for performing the services requested under this Agreement.

 

III. Director’s Representations
and Warranties

 

The Director represents and warrants that no other party has exclusive
rights to his services in the specific areas in which the Company is conducting business and that the Director is in no way compromising
any rights or trust between any other party and the Director or creating a conflict of interest as a result of his or her participation
on the Board.  The Director also represents, warrants and covenants that so long as the Director serves on the Board, the Director
will not enter into another agreement that will create a conflict of interest with this Agreement or the Company.  The Director further
represents, warrants and covenants that he or she will comply with the Company’s Articles, Bylaws, policies and guidelines, all
applicable laws and regulations, including Sections 10 and 16 of the Securities Exchange Act of 1934, as amended, and listing rules of
The Nasdaq Stock Market LLC or any other stock exchanges on which the Company’s securities may be traded; that if he or she is designated
by the Board as an independent director, he or she shall promptly notify the Board of any circumstances that may potentially impair his
or her independence as a director of the Company; and that he or she shall promptly notify the Board of any arrangements or agreements
relating to compensation provided by a third party to him or her in connection with his or her status as a director or director nominee
of the Company or the services requested under this Agreement.

 

Throughout the term of this Agreement, the Director agrees he or she
will not, without obtaining the Company’s prior written consent, directly or indirectly engage or prepare to engage in any activity
in competition with the Company’s business, products or services, including without limitation, products or services in the development
stage, accept employment or provide services to (including but not limited to service as a member of a board of directors), or establish
a business in competition with the Company; provided, however, that the Director may serve or continue to serve as an officer or director
of one or more entities that are affiliated with the Company, including without limitation, entities in which the Company does not have
a majority holding. 

 

     

     

    

 

IV. Compensation

 

A. Cash Fee

 

Subject to Section VI and during the term of this Agreement, commencing
on the date of this Agreement, the Company shall pay the Director, if the Company does not otherwise compensate the Director as an officer
or employee, a non-refundable fee of $2,000 per month in consideration for the Director providing the services described in Section I.
 This cash fee may be revised by action of the Board from time to time.  Such revision shall be effective as of the date specified
in the resolution for payments not yet earned and need not be documented by an amendment to this Agreement to be effective.  

 

B.  Expenses

 

During the term of this Agreement, the Company will reimburse the Director
for reasonable business related expenses approved by the Company in advance, such approval not to be unreasonably withheld.  Invoices
for expenses, with receipts attached, shall be submitted.  Such invoices must be approved by the Company’s Chief Executive
Officer or Chief Financial Officer as to form and completeness.

 

C. Equity Compensation

 

For his or her services as a director of the Company, the Director
is eligible to receive awards under the Company’s equity incentive plans as may from time to time be determined by the Board or
the administrator of such plan in its sole discretion.

 

V.  Term of Agreement and
Amendments

 

This Agreement shall be in effect from the date hereof through the
last date of the Director’s current term as a member of the Board.  This Agreement shall be automatically renewed on the date
of the Director’s reelection as a member of the Board for the period of such new term unless the Board determines not to renew this
Agreement.  Any amendment to this Agreement must be approved by the Board.  Amendments to Section IV “Compensation”
hereof do not require the Director’s consent to be effective.

 

VI. Termination

 

This Agreement shall automatically terminate upon the death of the
Director or upon his resignation or removal from, or failure to win election or reelection to, the Board.   In the event of
expiration or termination of this Agreement, the Director agrees to return or destroy any materials transferred to the Director under
this Agreement except as may be necessary to fulfill any outstanding obligations hereunder.  The Director agrees that the Company
has the right of injunctive relief to enforce this provision.

 

The Company’s and the Director’s continuing obligations
hereunder in the event of expiration or termination of this Agreement shall be subject to the terms of Section XII hereof.

 

VII. Limitation of Liability
and Force Majeure

 

Under no circumstances shall the Company be liable to the Director
for any consequential damages claimed by any other party as a result of representations made by the Director with respect to the Company
which are materially different from any to those made in writing by the Company.

 

Furthermore, except for the maintenance of confidentiality, neither
party shall be liable to the other for delay in any performance, or for failure to render any performance under this Agreement when such
delay or failure is caused by Government regulations (whether or not valid), fire, strike, differences with workmen, illness of employees,
flood, accident, or any other cause or causes beyond reasonable control of such delinquent party.

 

VIII. Confidentiality and
Use of Director Information

 

The Director agrees to sign and abide by the Company’s Director
Proprietary Information Agreement attached hereto as Exhibit A (the “Proprietary Information Agreement”).  

 

The Director explicitly consents to the Company holding and processing
both electronically and manually the information that he or she provides to the Company or the data that the Company collects which relates
to the Director for the purpose of the administration, management and compliance purposes, including but not limited to the Company’s
disclosure of any and all information provided by the Director in the Company’s proxy statements, annual reports or other securities
filings or reports pursuant to federal or state securities laws or regulations, and the Director agrees to promptly notify the Company
of any misstatement of a material fact regarding the Director, and of the omission of any material fact necessary to make the statements
contained in such documents regarding the Director not misleading.

 

    2

     

    

 

IX. Resolution of Dispute

 

Any dispute regarding this Agreement (including without limitation
its validity, interpretation, performance, enforcement, termination and damages) shall be determined in accordance with the laws of the
State of New York, the United States of America.  Any action under this paragraph shall not preclude any party hereto from seeking
injunctive or other legal relief to which each party may be entitled.

 

X. Entire Agreement

 

This Agreement (including agreements executed in substantially the
form of the exhibits attached hereto) supersedes all prior or contemporaneous written or oral understandings or agreements, and, except
as otherwise set forth herein, may not be added to, modified, or waived, in whole or in part, except by a writing signed by the party
against whom such addition, modification or waiver is sought to be asserted.

 

XI. Assignment

 

This Agreement and all of the provisions hereof shall be binding upon
and inure to the benefit of the parties hereto and their respective successors and permitted assigns and, except as otherwise expressly
provided herein, neither this Agreement, nor any of the rights, interests or obligations hereunder shall be assigned by either of the
parties hereto without the prior written consent of the other party.

 

XII. Notices

 

Any and all notices, requests and other communications required or
permitted hereunder shall be in writing, registered mail or by facsimile, to each of the parties at the addresses set forth above. Any
such notice shall be deemed given when received and notice given by registered mail shall be considered to have been given on the tenth
(10th) day after having been sent in the manner provided for above.

 

XIII. Survival of Obligations

 

Notwithstanding the expiration or termination of this Agreement, neither
party hereto shall be released hereunder from any liability or obligation to the other which has already accrued as of the time of such
expiration or termination (including, without limitation, the Director’s obligations under the Proprietary Information Agreement,
and the Company’s obligation to make any fees and expense payments required pursuant to Section IV due up to the date of the expiration
or termination) or which thereafter might accrue in respect of any act or omission of such party prior to such expiration or termination.

 

XIV. Severability

 

Any provision of this Agreement which is determined to be invalid or
unenforceable shall not affect the remainder of this Agreement, which shall remain in effect as though the invalid or unenforceable provision
had not been included herein, unless the removal of the invalid or unenforceable provision would substantially defeat the intent, purpose
or spirit of this Agreement.

 

XV. Counterparts

 

This Agreement may be executed in any number of counterparts, all of
which taken together shall constitute one instrument. Execution and delivery of this Agreement by facsimile or other electronic signature
is legal, valid and binding for all purposes.

 

(Remainder of page intentionally left blank)

 

    3

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed as of the date first written above.

 

	Director:	 	BIMI International Medical Inc.
	 	 	 	 	 
	By:	 	 	By:	 
	 	 , Director	 	 	Name:
	 	 	 	 	Title:

 

    4

     

    

 

EXHIBIT A

 

DIRECTOR PROPRIETARY INFORMATION AGREEMENT

 

THIS DIRECTOR PROPRIETARY INFORMATION AGREEMENT (the “Agreement”)
is made effective as of ______, 2021, by and between BIMI INTERNATIONAL MEDICAL INC., a Delaware corporation (“BIMI”),
and ________ (the “Director”).

 

WHEREAS, the Director has agreed to serve on the
Board of Directors of BIMI (the “Board”);

 

WHEREAS, the parties desire to assure the confidential
status of the information which may be disclosed by BIMI to the Director in connection with the Director serving on the Board; and

 

NOW THEREFORE, in reliance upon and in consideration
of the following undertaking, the parties agree as follows:

 

1.  Subject
to the limitations set forth in Paragraph 2, all information disclosed by BIMI to the Director shall be deemed to be “Proprietary
Information.”  In particular, Proprietary Information shall be deemed to include any information, process, technique, algorithm,
program, design, drawing, formula or test data relating to any research project, work in process, future development, engineering, manufacturing,
marketing, servicing, financing or personnel matter relating to BIMI, any of its affiliates or subsidiaries, present or future products,
sales, suppliers, customers, employees, investors, or business of BIMI or any of its affiliates or subsidiaries, whether or oral, written,
graphic or electronic form.

 

2.  The term
“Proprietary Information” shall not be deemed to include the following information: (i) information which is now, or hereafter
becomes, through no breach of this Agreement on the part of the Director, generally known or available to the public; (ii) is known by
the Director at the time of receiving such information; (iii) is hereafter furnished to the Director by a third party, as a matter of
right and without restriction on disclosure; or (iv) is the subject of a written permission to disclose provided by BIMI.

 

3.  The Director
shall maintain in trust and confidence and not disclose to any third party or use for any unauthorized purpose any Proprietary Information
received from BIMI.  The Director may use such Proprietary Information only to the extent required to accomplish the purposes of
his position at BIMI.  The Director shall not use Proprietary Information for any purpose or in any manner which would constitute
a violation of any laws or regulations, including without limitation the export control laws of the United States.  No other rights
of licenses to trademarks, inventions, copyrights, or patents are implied or granted under this Agreement.

 

4.  Proprietary
Information supplied shall not be reproduced in any form except as required to accomplish the intent of this Agreement.

 

5.  The Director
represents, warrants and covenants that he shall protect the Proprietary Information received with at least the same degree of care used
to protect his or her own Proprietary Information from unauthorized use or disclosure. 

 

    5

     

    

 

6.  All Proprietary
Information (including all copies thereof) shall remain in the property of BIMI, and shall be returned to BIMI (or destroyed) after the
Director’s need for it has expired, or upon request of BIMI, and in any event, upon the expiration or termination of that certain Board
of Directors Agreement, of even date herewith, between BIMI and the Director (the “Director Agreement”).

 

7.  Notwithstanding
any other provision of this Agreement, disclosure of Proprietary Information shall not be precluded if such disclosure:

 

(a) is in response to a valid order,
including a subpoena, of a court or other governmental body of the United States or any political subdivision thereof; provided, however,
that to the extent reasonably feasible, the Director shall first have given BIMI notice of the Director’s receipt of such order
and BIMI shall have had an opportunity to obtain a protective order requiring that the Proprietary Information so disclosed be used only
for the purpose for which the order was issued;

 

(b) is otherwise required by law; or

 

(c) is otherwise necessary to establish
rights or enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary.

 

8.  This Agreement
shall continue in full force and effect during the term of the Director Agreement.  This Agreement may be terminated at any time
thereafter upon thirty (30) days written notice to the other party.  The termination of this Agreement shall not relieve the Director
of the obligations imposed by Paragraphs 3, 4, 5 and 11 of this Agreement with respect to Proprietary information disclosed prior to the
effective date of such termination and the provisions of these Paragraphs shall survive the termination of this Agreement indefinitely
with respect to Proprietary Information that constitutes “trade secrets” and for a period of eighteen (18) months from the
date of such termination with respect to other Proprietary Information.

 

9. This Agreement
shall be governed by the laws of the State of New York.

 

10.  This Agreement
contains the final, complete and exclusive agreement of the parties relative to the subject matter hereof and may not be changed, modified,
amended or supplemented except by a written instrument signed by both parties.

 

11.  Each party hereby
acknowledges and agrees that in the event of any breach of this Agreement by the Director, including, without limitation, an actual or
threatened disclosure of Proprietary Information without the prior express written consent of BIMI, BIMI will suffer an irreparable injury,
such that no remedy at law will afford it adequate protection against, or appropriate compensation for, such injury.  Accordingly,
each party hereby agrees that BIMI shall be entitled to specific performance of the Director’s obligations under this Agreement, as well
as such further injunctive relief as may be granted by a court of competent jurisdiction.

 

	Director:	 	 	BIMI International Medical Inc.
	 	 	 	 	 
	Signature:	 	 	Signature:	 
	Print Name:	 	 	Print Name:	 
	Title:	 	 	Title:	 

 

 

6Exhibit 10.4

 

Form of Warrants

 

The warrants (the “Warrants”) referred
to in the Payment Section of this Agreement, and described more thoroughly in this Annex, shall be formally drawn up into executable
contracts by the Client’s counsel. The Client does hereby agree to cover all related expenses, save for any that the Warrant Holders
may choose to incur from their own attorneys to review and/or provide recommendations regarding the Warrants.

 

As of the Effective Date of this Agreement the Client
does not have enough issued Common Stock (the “Shares”) from its Authorized Shares and requires one or more corporate actions
to meet the terms and conditions of the Warrants. As such, the Signatory of this Agreement does hereby guarantee that, should the Client
not be in a position, for any reason, to make full delivery of its Shares, according to the terms and conditions specified in the Warrants,
that the Signatory will make such Shares available from his/her own (personal) holdings, or the holdings of any affiliated organizations,
trusts, entities, and the like that he/she controls.

 

It is understood and agreed that the Client owes EGS
the Warrants described herein, and is committed to provide such Warrants, as of the Effective Date.

 

The following Basic Business Terms and Conditions
are not exhaustive and are subject to modification upon mutual agreement of the Signatories of this Agreement.

 

Article II. Basic
Business Terms and Conditions

 

	 	1.	Purchase of Shares. Subject to the terms and conditions hereinafter set forth, the holder of this Warrant is entitled, upon surrender of this Warrant at the principal office of the Client (or at such other place as the Client shall notify the holder hereof in writing), to purchase from the Client up to 25,000 fully paid and nonassessable shares of the Shares at an exercise price of $0.10 per Share (such price, as adjusted from time to time, is herein referred to as the “Exercise Price”).
	 	 	 
	 	2.	Exercise Period. This Warrant shall be exercisable, in whole or in part, on or after 9:00 am Eastern Time, January 1st, 2020, and until 5:00pm Eastern Time, December 29th, 2023 (the “Exercise Period”).
	 	 	 
	 	3.	Method of Exercise. While this Warrant remains outstanding and exercisable in accordance with the terms and condition herein, the holder may exercise from time to time, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be affected by:
	 	 	 
	 	 	3.1.	the surrender of the Warrant, together with a notice of exercise to the Secretary of the Client at its principal offices; and
	 	 	 	 
	 	 	3.2.	the payment to the Client of an amount equal to the aggregate Exercise Price for the number of Shares being purchased.
	 	 	 
	 	4.	Certificates for Shares; Amendments of Warrants. Upon the exercise of the purchase rights evidenced by this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within thirty (30) days of the delivery of the subscription notice. Upon partial exercise, the Client shall promptly issue an amended Warrant representing the remaining number of Shares purchasable thereunder. All other terms and conditions of such amended Warrant shall be identical to those contained herein. The above notwithstanding, the Shares may be delivered electronically, and held in Street Name, in accordance with industry and regulatory norms.

 

    	 

     

    

 

	 	5.	Issuance
    of Shares. The Client covenants that (i) the Shares, when issued pursuant to the exercise of this Warrant, will be duly and validly
    issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof, (ii) during
    the Exercise Period the Client will reserve from its authorized and unissued Common Stock sufficient Shares in order to perform its
    obligations under this warrant.
	 	 	 
	 	6.	Adjustment
    of Exercise Price and Number of Shares. The number of and kind of securities purchasable upon exercise of this Warrant and the
    Exercise Price shall be subject to adjustment from time to time as follows:

 

	 	6.1.	Subdivisions,
    Combinations and Other Issuances. If the Client shall at any time before the expiration of this Warrant subdivide the Shares,
    by split-up or otherwise, or combine its Shares, or issue additional shares of its Shares as a dividend, the number of Shares issuable
    on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately
    decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the
    aggregate purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same.
    Any adjustment under this Section shall become effective at the close of business on the date the subdivision or combination becomes
    effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend.
	 	 	 
	 	6.2.	Reclassification,
    Reorganization and Consolidation. In case of any reclassification, capital reorganization, or change in the capital stock (including
    because of a change of control) of the Client (other than as a result of a subdivision, combination, or stock dividend provided for
    in Section 6.1 above), then the Client shall make appropriate provision so that the holder of this Warrant shall have the right at
    any time before the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant,
    the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization,
    or change by a holder of the same number of Shares as were purchasable by the holder of this Warrant immediately before such reclassification,
    reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the holder
    of this Warrant so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities
    and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable
    hereunder, provided the aggregate purchase price shall remain the same.
	 	 	 
	 	6.3.	Notice
    of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the Warrant,
    or in the Exercise Price, the Client shall promptly notify the holder of such event and of the number of Shares or other securities
    or property thereafter purchasable upon exercise of this Warrant.

 

	 	7.	No
    Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
    this Warrant, but in lieu of such fractional shares the Client shall make a cash payment therefor on the basis of the Exercise Price
    then in effect.
	 	 	 
	 	8.	Representations
    of the Client. The Client represents that all corporate actions on the part of the Client, its officers, directors and stockholders
    necessary for the sale and issuance of this Warrant have been taken.
	 	 	 
	 	9.	Representations
    and Warranties by the Holder(s). The Holder(s) represents and warrants to the Client as follows:

 

	 	9.1.	The
    Holder(s) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks
    of the purchase of this Warrant and the Shares purchasable pursuant to the terms of this Warrant and of protecting its interests
    in connection therewith.
	 	 	 
	 	9.2.	The
    Holder(s) is able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant.

 

	 	10.	Warrants
    Transferable. Subject to compliance with the terms and conditions of this Section, this Warrant and all rights hereunder are
    transferable, without charge to the holder hereof (except for transfer taxes), upon surrender of this Warrant properly endorsed or
    accompanied by written instructions of transfer. With respect to any offer, sale or other disposition of this Warrant or any Shares
    acquired pursuant to the exercise of this Warrant before registration of such Warrant or Shares.
	 	 	 
	 	11.	Rights
    of Shareholders. No Holder of this Warrant shall be entitled, as a Warrant Holder, to vote or receive dividends or be deemed
    the holder of the Shares or any other securities of the Client which may at any time be issuable on the exercise hereof for any purpose,
    nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a stockholder
    of the Client or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof,
    or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of
    stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends
    or subscription rights or otherwise until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof
    shall have become deliverable, as provided herein.
	 	 	 
	 	12.	Governing
    Law. This Warrant and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance
    with the laws of New York, without regard to the conflicts of law provisions of New York or of any other state.
	 	 	 
	 	13.	Rights
    and Obligations Survive Exercise of Warrant. Unless otherwise provided herein, the rights and obligations of the Client, of the
    holder of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this
    Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]